Aims/hypothesis Liver X receptors (LXRs) α and β are nuclear hormone receptors that are widely expressed in the kidney. They promote cholesterol efflux from cells and inhibit inflammatory responses by regulating gene transcription. Here, we hypothesised (1) that LXR deficiency would promote renal decline in a mouse model of diabetes by accelerating intraglomerular cholesterol accumulation and, conversely, (2) that LXR agonism would attenuate renal decline in diabetes.
Introduction
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease, accounting for 44% of new cases each year [1] . Hyperglycaemia and hypertension are established causes of DN; however, elevated plasma lipids are also linked with progression to microalbuminuria [2] . Several investigators have hypothesised that lipids play a causal role in the progression of chronic kidney disease, noting the similarities between the pathogenesis of atherosclerosis and glomerulosclerosis. These include: influx of monocytes, build-up of lipid-laden cells, and the presence of cholesterol and cholesteryl esters [3] [4] [5] . Several cross-sectional studies of patients with type 1 diabetes have indicated that elevated apolipoprotein B or LDL-cholesterol and/or decreased levels of HDL-cholesterol are associated with progression of albuminuria [6] [7] [8] [9] [10] . Moreover, experiments in animal models of diabetes fed a Western diet have also supported the notion that sustained lipid abnormalities accelerate the progression of DN [11] [12] [13] [14] .
The liver X receptors (LXRs) α and β are nuclear hormone receptors. They are activated by endogenous oxysterols, which are natural products derived from the metabolism of cholesterol. LXRs are considered to be intracellular 'cholesterol sensors' because they activate transcription in response to cholesterol metabolites [15] . LXR activation by a synthetic ligand was atheroprotective in animal models of dyslipidaemia [16] . Mechanistically, this atheroprotective effect has been attributed to enhanced reverse cholesterol transport and inhibition of inflammatory responses upon LXR activation [16, 17] . Direct LXR target genes include those encoding the ATP-binding cassette (ABC) transporter A1 (ABCA1) and the ABC transporter G1 (ABCG1), which govern cholesterol efflux from macrophages and peripheral organs, and the inducible degrader of LDL receptor (Idol [also known as Mylip]), which decreases LDL receptor protein levels and peripheral cholesterol uptake [18, 19] . In macrophages, LXR activation inhibits the expression of inflammatory cytokines (i.e. IL-1β, IL-6 and TNFα) [20, 21] , monocyte chemoattractant protein and osteopontin [22] . Unfortunately, first-generation LXR agonists (T0901317, GW3965) caused hypertriacylglycerolaemia through upregulation of hepatic sterol regulatory element-binding protein 1c (SREBP1c) [23] . N ,N -Dimethyl-hydroxycholenamide (DMHCA) is a new-generation LXR gene-selective agonist, which reduces plaque formation in animal models of atherosclerosis without inducing hypertriacylglycerolaemia [24, 25] .
Human biopsies and experimental rodent models have revealed a consistent downregulation of LXRs in DN compared with control [26, 27] , and experiments with firstgeneration LXR ligands have shown anti-inflammatory and anti-albuminuric actions in diabetic mice [28, 29] . While these observations are promising for the development of DN therapies targeting LXRs, several fundamental questions remain. First, whereas LXR agonism may slow renal decline, the effects of LXR downregulation (as observed in patients) on the natural progression of renal decline are unknown. Second, although LXRs appear to prevent inflammation within the renal tubulointerstitium, the role of these receptors in preserving glomerular homeostasis is incompletely defined, considering the importance of glomerular injury in the pathogenesis of DN and the broad range of LXR target genes. Finally, while first-generation LXR agonists have provided proof of concept for the biological importance of this pathway in DN, they are not clinical drug candidates because of their undesirable effects on plasma and liver triacylglycerol levels. To address these deficiencies, we performed experiments in Lxrα/β −/− (Lxrα, also known as Nr1h3; Lxrβ, also known as Urine and plasma analyses Blood was collected into EDTAcoated tubes and plasma was analysed using commercially available assays (see ESM Methods for further details).
Histology and immunofluorescence One kidney was sectioned for paraffin embedding (fixed in formalin), optimal cutting temperature compound (OCT) embedding (fixed in formalin then sucrose-protected in a 10% wt/vol. and 30% wt/vol. sucrose solution) and electron microscopy (fixed in glutaraldehyde). See ESM Methods for details on staining and quantification.
Kidney lipid analysis Tissues were digested in chloroform : methanol (2:1) with a 20:1 volume to tissue ratio, and processed as described previously [30] .
RNA isolation and gene expression analysis RNA was isolated and cDNA synthesised as described previously [30] . Gene expression levels were measured by high-throughput real-time quantitative PCR (7900HT; Applied Biosystems, Foster City, CA, USA) using the 2 −ΔΔC t method and normalised to cyclophilin. Primer sequences are given in ESM mice, and this was further increased by twofold after STZ treatment (Fig. 1e ). Total kidney cholesterol was higher in Lxrα/β −/− mice, while triacylglycerol tended to be lower, but there were no significant differences between groups (Table 1) . Plasma cholesterol levels remained constant in all treatment groups and plasma triacylglycerol levels were lower in Lxrα/β −/− than in Lxrα/β +/+ mice (Table 1) .
To determine whether decreased cholesterol export contributed to the increase in glomerular lipids in Lxrα/β −/− mice, we examined the LXR target genes Abca1 and Abcg1 (cholesterol efflux transporters). There was no change in the basal expression of Abcg1 , while Lxrα/β −/− mice had decreased mRNA levels of Abca1 (ESM Fig. 2a ). Western blot analysis of ABCA1, however, showed no significant difference between groups (ESM Fig. 2c ). Likewise, no significant difference was observed between groups in genes important to the cholesterol biosynthetic pathway, e.g. Srebp2 (also known as Srebf2 ) and Hmgcr (ESM Fig. 2a ). To establish whether triacylglycerol synthesis was altered, we measured the LXR target genes Srebp1c (also known as Srebf1) and Scd1. While Srebp1c expression was significantly reduced in vehicle-treated Lxrα/β −/− kidney, this baseline reduction was blunted in STZ-treated Lxrα/β −/− mice, although its relative expression still remained lower than in STZ-treated Lxrα/β +/+ mice. Scd1 also showed a trend towards a baseline decrease in non-diabetic Lxrα/β −/− mice compared with Lxrα/β +/+ mice; this decrease was significantly blunted in response to STZ treatment (ESM Fig. 2a ). The expression of fatty acid oxidation genes (Ppara , Acox1 , Cpt1a) was unchanged between genotypes (ESM Fig. 2a ). Taken together, these data suggest that the accumulation of neutral lipids in the glomeruli of STZ Lxrα/β −/− mice compared with STZ Lxrα/β +/+ mice cannot be explained by decreased cholesterol efflux, decreased fatty acid oxidation, or increased cholesterol or triacylglycerol synthesis.
Lipoprotein uptake in the kidney is primarily mediated through the LDL receptor with some contribution from scavenger receptors [33, 34] . The scavenger receptor encoded by Cd36 was moderately decreased in Lxrα/β −/− compared with Lxrα/β +/+ mice, but not significantly altered by diabetes (ESM Fig. 2b ). In contrast, mRNA and protein levels of the oxidised-LDL (ox-LDL) receptor (OLR1) were increased in diabetic Lxrα/β −/− mice (Fig. 2a, b) . With a focus on lipid uptake, we found that the expression of Idol, which regulates LDL receptor expression and is an LXR target gene, was significantly decreased in Lxrα/β −/− mice ( (Fig. 2d) . Electron microscopy of glomeruli from Lxrα/β −/− mice showed increased lipid droplets after STZ treatment, these being localised to the mesangial matrix (Fig. 2e) . Together, these data suggest that, although STZ Lxrα/β −/− mice have total circulating cholesterol levels similar to mice in other groups, the extensive accumulation of lipids in their glomeruli may be due to increased uptake and/or increased retention of circulating lipids. (Fig. 3a) . Diabetic Lxrα/β −/− samples had the most severe pathological changes and were the only group with hyalinotic lesions (Fig. 3b) . Semiquantitative scoring of sections revealed an 18-fold increase in mesangial matrix expansion in the diabetic Lxrα/β −/− samples compared with diabetic Lxrα/β +/+ mice and a sevenfold increase in diabetic compared with non-diabetic Lxrα/β −/− mice (Fig. 3c) . Gene expression analyses showed significant increases in markers of renal fibrosis, including genes contributing to the extracellular matrix, e.g. Fn1 and Col1a2 (Fig. 3d, e) , as well as those encoding profibrotic growth factors, e.g. Tgfβ (also known as Tgfb1) and Ctgf (Fig. 3f, g ). The TGFβ target genes, Col1a2 and Ctgf, were only significantly increased in STZ-treated Lxrα/β −/− mice, remaining unchanged in all other groups. No evidence of interstitial fibrosis was noted by histological analysis and no changes in the expression of α-smooth muscle actin, a marker of collagen-producing myofibroblasts, were observed (data not shown).
Diabetic Lxrα/β −/− mice had elevated proinflammatory and oxidative stress markers LXRs are important determinants of inflammatory signalling. To assess local kidney inflammation, we analysed kidney sections for CD45 leucocyte staining and measured the gene expression of the inflammatory markers Tlr2 , Il1b, Icam1 and Opn (also known as Spp1), all of which are known to be dysregulated in DN. The number of CD45 cells in the glomeruli tended to increase in STZ-treated animals compared with controls, as well as basally in Lxrα/β −/− mice compared with Lxrα/β +/+ mice (Fig. 4a, b) . Consistent with these data, all inflammatory genes showed their highest expression levels in diabetic Lxrα/β −/− mice, including the macrophage marker Cd68 (Fig. 4c-g ).
Oxidative stress and inflammation are highly intertwined in pathological states. A key mediator of oxidative stress is the multiprotein NADPH oxidase (NOX) system. NOX2 and its functional partner p47 phox are critical for the progression of DN. Consistent with an increased inflammatory response, Nox2 (also known as Cybb ) and p47 phox (also known as Ncf1) were elevated in Lxrα/β −/− mice compared with their Lxrα/β +/+ counterparts (Fig. 4h, i) . Physiologically, oxidative stress can result in increased lipid peroxidation. As a surrogate marker, we measured malondialdehyde (MDA) and found a significant increase in urinary MDA in STZ Lxrα/β +/+ and Lxrα/β −/− animals compared with non-diabetic controls.
Furthermore, non-diabetic Lxrα/β −/− mice had a trend towards increased urinary MDA compared with Lxrα/β +/+ mice (Fig. 4j) , suggesting that Lxrα/β −/− mice have an increased basal level of oxidative stress.
Treatment with an LXR agonist attenuated proteinuria and glomerular injury in diabetic DBA/2J mice To explore whether LXR activation could delay the onset of DN, we treated STZ-injected DBA/2J mice that were on a Western diet with vehicle or an LXR agonist for 10 weeks. We used DMHCA (instead of GW3965 or T091317) to avoid upregulation of hepatic SREBP1c and thus hypertriacylglycerolaemia and hepatic steatosis [25] . As anticipated, diabetic DBA/2J mice had twofold higher urinary ACR compared with non-diabetic mice, this increase being abolished with DMHCA (Fig. 5a ). We measured urinary nephrin to assess podocyte integrity. There was a sixfold increase in nephrin excretion in STZ-treated DBA/2J mice compared with non-diabetic mice; this increase was reduced by 50% with DMHCA (Fig. 5b) . To ensure that DMHCA was not activating other pharmacological targets, we studied STZ-injected Lxrα/β −/− mice on a Western diet (with or without DMHCA) for 14 weeks. As anticipated, the ACR was unchanged in Lxrα/β −/− mice in response to DMHCA (Fig. 5c ). In STZ DBA/2J mice, DMHCA improved the glomerular structure, decreasing mesangial expansion and reducing foam cell formation on PAS-stained sections (Fig. 5d) . Although other LXR ligands have been implicated in repression of the renin-angiotensin system (RAS), we found no differences in renin or Ace expression in response to DMHCA (ESM Fig. 3b ) or in STZ-treated Lxrα/β −/− mice compared with STZ Lxrα/β +/+ mice (ESM Fig. 2b ). Neither DMHCA nor loss of LXRα and LXRβ affected systolic blood pressure (ESM Fig. 4 ). Animals treated with DMHCA showed no significant change in glucose levels ( Table 2 ), suggesting that the improvement in renal function was independent of hyperglycaemia.
Treatment with an LXR agonist decreased inflammation and lipid accumulation in kidneys of diabetic DBA/2J mice To assess inflammation in the DBA/2J model of diabetes, we examined inflammatory markers known to be dysregulated in DN. CD68 infiltration was markedly induced with diabetes and then attenuated in diabetic mice treated with DMHCA (Fig. 6a) . Consistent with these results, the mRNA expression levels of Tlr2, Icam1, Opn and Cd68 were increased with diabetes and returned to non-diabetic levels upon DMHCA treatment (Fig. 6b-e) . Furthermore, in diabetic mice treated with DMHCA, we found decreased Nox2 mRNA (Fig. 6f) and a significant decrease in levels of urinary MDA (Fig. 6g) .
We next determined whether changes in neutral lipids correlated with the severity of DN in this animal model. Diabetic DBA/2J mice had increased glomerular Oil Red O staining, which was significantly attenuated with DMHCA (Fig. 7a) . We explored pathways important to cholesterol efflux, synthesis and uptake, our aim being to determine whether these could explain changes in renal cholesterol handling. Surprisingly, mRNA levels of Abca1 and Abcg1 were not significantly altered by DMHCA, but protein levels of ABCA1 tended to increase in DMHCA STZ mice (1.3-fold compared with vehicle-treated STZ) (ESM Fig. 3a, Fig. 7b) . No significant differences in Hmgcr or Srebp2 mRNA were observed (ESM Fig. 3a) , while a trend towards increased Srebp1c and Scd1 (in the kidney) was observed only in non-diabetic animals (ESM Fig. 3a) . Expression of Cd36 (mRNA) and Olr1 (mRNA and protein), which are both involved in ox-LDL uptake, were not changed during DMHCA treatment in STZ-treated mice (ESM Fig. 3b, c) . To assess whether DMHCA acted directly at the kidney, we measured tissue drug levels by LC/MS/MS. DMHCA was detectable in STZ-treated mice, but not in non-diabetic mice, suggesting that DMHCA does indeed reach the kidney and that renal clearance of DMHCA is impaired with diabetes (Fig. 7c) . The expression of Lxrα was decreased with STZ and normalised to non-diabetic levels with DMHCA, with a similar trend being observed for Lxrβ (Fig. 7d, e) . Likewise, the LXR target gene Idol was increased with DMHCA in the kidney of STZ-injected mice (Fig. 7f) , suggesting that lipoprotein uptake in the kidney may be decreased.
DMHCA significantly improved systemic lipid homeostasis Liver cholesterol content decreased 40% in mice treated with DMHCA compared with vehicle (Fig. 7g) . In contrast to other LXR ligands, DMHCA also decreased liver triacylglycerol (Fig. 7h) . These changes were supported by liver gene expression, with an increase in Cyp7a1 (which encodes a cholesterol metabolising enzyme) (Fig. 7i) and a decrease in the lipogenic gene Srebp1c (Fig. 7j) , consistent with DMHCA being a gene-selective regulator of LXR. Remarkably, we observed a 48% decrease in plasma cholesterol and a 70% decrease in plasma triacylglycerol levels in DMHCA-treated vs vehicle-treated diabetic mice (Table 2 ). Together these data support a favourable role for LXR activation in mitigating the progression of DN through several mechanisms, including 
Discussion
New pharmacological targets are urgently needed to counteract progressive renal decline in patients with DN. In the present study, we demonstrate that LXRs play an essential role in LXRα and LXRβ are involved in normal renal function with known actions on the RAS and high expression in the kidney [35, 36] , including mesangial cells [37] , glomerular endothelial cells and proximal tubular cells [38] . Previous studies have shown that activation of LXR with T091317 resulted in inhibition of isoprenaline-induced activation of RAS (without affecting blood pressure) [39] , while treatment of angiotensin II-infused mice with GW3965 decreased expression of At1r (also known as Agtrap), Ace and renin, with a concomitant decrease in systolic blood pressure [40] . In our studies, we found that DMHCA treatment did not change renin or Ace expression, and LXR agonism or genetic knockout did not affect systolic BP. Therefore, the association we observed between glomerular lipid accumulation and other indices of diabetic renal injury are unlikely to be a consequence of LXR-mediated RAS-dependent actions, although these analyses need to be repeated with a larger cohort of mice.
Interestingly [28, 29] ; however, these studies were unable to address the importance of LXR in baseline renal function. The authors attributed the improvement in renal function to inhibition of the proinflammatory gene osteopontin in renal tubular cells [29] or to enhanced activity of macrophage LXRα [28] . In contrast, our data, supported by loss of function and gain of function (using a gene-selective LXR ligand), suggest a more complex mechanism, which includes protection from lipid deposition in the glomerulus and inhibition of renal inflammation. The reason for the preferential increase in glomerular lipids in diabetic Lxrα/β −/− is still not clear. Oxidised-LDL has been previously shown to have a five-to tenfold greater affinity for uptake into mesangial cells than LDL [44] . We considered the possibility that ox-LDL may be more abundant in STZ-treated Lxrα/β −/− mice, but found no significant difference in plasma ox-LDL between groups (Table 1) . We also measured the uptake of fluorescently labelled ox-LDL in STZ Lxrα/β −/−
and Lxrα/β +/+ kidneys, but found no difference at 30 min post infusion (data not shown). These data suggest that ox-LDL is not responsible for the glomerular lipid accumulation. Preferential uptake by the LDL receptor, a key lipoprotein carrier in the kidney [34] , remains a plausible explanation. Alternatively, increased proteoglycan deposition as occurs in DN has also been recently shown to increase lipoprotein retention [45] .
There are several limitations to our study. Gene expression analyses were performed on whole kidney, but greater changes might have been observed in isolated glomeruli, where the pathological state was primarily located. Our mice exhibited varying sensitivities to STZ, which left the number of animals in some groups lower than anticipated. We did not perform an exhaustive survey of the RAS; however, it is notable that Lxrα/β −/− mice have previously been shown to have a blunted response to isoprenaline, suggesting that Lxrα/β −/− mice would be protected against (not susceptible to) hypertension [46] . DMHCA was very effective at decreasing circulating cholesterol and triacylglycerol levels with additional beneficial effects on liver lipid levels. Therefore, despite the accumulation of DMHCA in the diabetic kidney, we cannot specifically define the contribution of renal vs systemic LXR activation to the improvement of DN. Nonetheless, cultured kidney mesangial cells treated with T0901317 showed increases in Abca1 promoter activity and cholesterol efflux, suggesting that LXR is functional in this cell type and could contribute to the clearance of glomerular lipids [37] . Finally, due to the assessment of renal histology at a single time point, it is not clear whether glomerular lipids accumulate before or after the recruitment of inflammatory cells. Inflammatory cytokines can repress the expression of LXR and its target genes [47] , and induce lipid accumulation [48] , whereas lipids can induce the expression of inflammatory cytokines [49, 50] . Thus, there is evidence supporting both scenarios. Regardless of the above, the activation of LXR is expected to inhibit both processes, suggesting it may be an ideal pharmacological target for DN. In summary, our study highlights the importance of cholesterol homeostasis (independently of hyperglycaemia) in the development and severity of DN. In light of our findings, we propose that intraglomerular lipid accumulation will be more reflective of disease progression than plasma lipids. The data support the notion that (1) LXR plays an important basal role in the kidney and (2) pharmacological activation of LXR using a gene-selective agonist that does not cause hypertriacylglycerolaemia could be a novel approach to delaying the progression of DN.
